KAI Pharmaceuticals Announces Initiation Of Phase 1b Study Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT)

Links shared publicly online about this topic.

  • 838
    total visits

KAI Pharmaceuticals Announces Initiation Of Phase 1b Study Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT)

medicalnewstoday.com —

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent b

View full resource at medicalnewstoday.com

Tags: Parathyroid Disorder, Drug, Pharma

  • Share

Most Recently Shared on September 29, 2010 at 2:05 pm By:

mnt_endocrine MNT Endocrinology

KAI Pharmaceuticals Announces Initiation Of Phase 1b Study Of KAI-4169 For The Treatment Of Secondary Hyperparathyroid... http://mnt.to/3Kth

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Urology MNT Urology

Advertisement